Zelluna Immunotherapy Revenue and Competitors
Estimated Revenue & Valuation
- Zelluna Immunotherapy's estimated annual revenue is currently $5.1M per year.
- Zelluna Immunotherapy's estimated revenue per employee is $155,000
Employee Data
- Zelluna Immunotherapy has 33 Employees.
- Zelluna Immunotherapy grew their employee count by 3% last year.
Zelluna Immunotherapy's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | COO & Head business development | Reveal Email/Phone |
3 | Scientist | Reveal Email/Phone |
4 | Research scientist | Reveal Email/Phone |
Zelluna Immunotherapy Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Zelluna Immunotherapy?
Zelluna Immunotherapy is a company developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of solid cancers. The company is developing a unique portfolio of tumor specific TCR's that target the MHC class II pathway to broadly engage the host immune system to provide a safe, efficient and durable clinical response. The company is developing therapies based on the effector functions of autologous T cells (TCR-T) and allogeneic NK cells (TCR-NK). Both of these platforms have their unique advantages and provides the opportunity to attack cancers from multiple angles and improve access to these advanced therapies to a large patient population. For more info please visit www.zelluna.com
keywords:N/A
N/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zelluna Immunotherapy News
Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6M | 33 | -43% | N/A |
#2 | $7.5M | 33 | 3% | N/A |
#3 | $4.8M | 33 | 32% | N/A |
#4 | $4.2M | 33 | 6% | N/A |
#5 | $6.7M | 33 | 0% | N/A |